News
GlobalData on MSN18h
Cardurion concludes enrolment in Phase II trials for heart failure treatmentUS-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback